“High-Cost Drugs”

72 result(s)
Female caregiver and elderly patient discussing medical information on a couch
Specialty
Safer Options for Infusion Treatments
Research published by Coram shows that helping patients transition to at-home or ambulatory center infusion treatments can be beneficial to both patients and payors. More
Briefing
Icon of an infusion bag, overlaying a rising line graph
Specialty
Managing the MS Cost Challenge
Multiple Sclerosis is a $19 billion market worldwide, and the third most expensive specialty drug spend category. Recently approved Ocrevus is likely to add to cost of treatment... More
Briefing
Drug Pipeline
What's Next for Hemophilia Treatments?
What's Next for Hemophilia Therapy and New Treatment Options? More
Briefing
Specialty
High-Touch, Whole Patient Care for PAH
PAH is a rare, life-threatening disease, which is incurable. It is difficult to manage and to help ensure the longest survival and best possible quality of life, members need... More
Briefing
Specialty
Three Major Challenges Facing Gene Therapy
The Top Challenges Facing Gene Therapy Today More
Briefing
Public Policy
RxSavingsPlus
RxSavingsPlus Provides Savings for Members without Pharmacy Benefits More
Video
Cost Management
Reducing Wasteful Spend on High-Cost, Low-Value Drugs
CVS Health’s Hyperinflation Strategy Helps Clients Reduce Unnecessary Drug Spend More
Briefing
Drug Pipeline
A Q2 2022 Look at Projected Gene Therapies and Approval Timelines
A Q2 2022 Look at Projected Gene Therapies and FDA Approval Timelines More
Briefing
Drug Pipeline
Treatment Options Expand in Robust Gene Therapy Pipeline
New Gene Therapies for Sickle Cell Disease, Hemophilia on the Horizon More
Briefing
Drug Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline
Breakthrough Therapies and New Biologics Feature in the Gene Therapy Pipeline More
Briefing